schizophrenia. Schizophrenia
Conditions
Interventions
Intervention 1: Intervention group: Tablet Risperidone (4-6 mg/day) combined with 200 mg/day Resveratrol as intervention group for 8 weeks. Intervention 2: Control group: Tablet Risperidone (4-6 mg/d
Treatment - Drugs
Placebo
Intervention group: Tablet Risperidone (4-6 mg/day) combined with 200 mg/day Resveratrol as intervention group for 8 weeks
Control group: Tablet Risperidone (4-6 mg/day) combined with placebo as control group for 8 weeks
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Diagnosis of Schizophrenia based on DSM-5 criteria Age between 18-60 Chronic Schizophrenia- duration of the disorder more than 2 years Minimum score of 20 in negative sub score being stable on risperidone( 4 to 6 mg per day) for the last 2 months
Exclusion criteria
Exclusion criteria: Any serious medical or neurological problem IQ less than 70. Substance dependence during the last 6 months(except for nicotine and caffeine) Score on HDRS less than 14 receiving ECT during the last 3 months Acute or chronic systemic diseases History of neurosurgery History of head trauma
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of schizophrenia. Timepoint: Baseline and weeks 2-4-8 after beginig of treatment. Method of measurement: by Positive and Negative Symptoms Scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShahin Akhondzadeh
Tehran University of Medical Sciences
Outcome results
None listed